Trial Profile
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CheckMate057
- Sponsors Bristol-Myers Squibb
- 06 Nov 2019 Results analysing the accuracy of different extrapolations performed at early data cuts in predicting realised long-term life years based on the CheckMate 057 study of nivolumab presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 10 Sep 2019 Results of Taylor-Expansion Adjustment for Survival Analyses in Immunotherapy Trials, presented at the 20th World Conference on Lung Cancer.
- 10 Sep 2019 Five-Year outcomes from the randomized, phase 3 trials CheckMate 017/057; results presented at the 20th World Conference on Lung Cancer